When entered as a block after all other terms, there were no significant interactions between treatment selleck kinase inhibitor conditions and baseline level of nicotine dependence, gender, or depression proneness in predicting changes in positive affect prior to quitting (prequit slope). To illustrate these results, Figure 1 displays changes in positive affect during treatment for smokers receiving bupropion and placebo who were classified as high and low using the median score from the DPI assessed prior to treatment. Figure 1. Changes in positive affect, negative affect, and urges to smoke among smokers with high and low levels of depression proneness (median split). BUP, bupropion; PLAC, placebo; and DPI, Depression Proneness Inventory. Negative affect. Treatment conditions did not differ in levels of negative affect upon entering treatment, F(3, 511) = 1.

02, p > .10 (Table 1). Overall, there was a small and statistically significant increase in negative affect between s1 and s5 in the week prior to quit date (means1 ? means5 = 0.85, 95% CI = 0.33�C1.38, d = 0.17, p < .001). As demonstrated in Table 2, in growth model analyses, neither bupropion nor CBT were related to changes in negative affect prior to quit day (prequit slope). Level of depression proneness was related strongly to higher levels of negative affect upon entry into treatment (prequit intercept) and was not related to changes prior to quit day. When entered as a block after all other terms, there were no significant interactions between treatment conditions and baseline covariates or depression proneness in predicting changes in negative affect prior to quitting (prequit slope).

Figure 1 displays changes in negative affect during treatment for smokers receiving bupropion and placebo who were classified as high and low using the median score from the DPI assessed prior to treatment. Urges to smoke. Treatment conditions did not differ in levels of urges to smoke upon entering treatment, F(3, 511) = 0.83, p > .10 (Table 1). Overall, there was a statistically significant decrease in urges to smoke between s1 and s5 in the week prior to quit date (means1 ? means5 = ?3.04; 95% CI = ?3.64 to ?2.43, d = ?0.57, p < .001). As illustrated in Table 2, in growth model analyses, bupropion and CBT were not related significantly to changes in urges to smoke prior to quit day (prequit Drug_discovery slope). Level of dependence was strongly related to level of urges upon entry into treatment. Level of depression proneness was not related to urges to smoke upon entry into treatment or changes in urges prior to quit day. There were no significant interactions between treatment conditions and baseline covariates or depression proneness in predicting changes in urges to smoke prior to quitting (prequit slope).